2026 Q2 - tulosraportti
88 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,40%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 400 | ||
| 5 237 | ||
| 6 000 | ||
| 6 000 | ||
| 6 000 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·1 t sittenI have summarized this week's most important Novo news in this post: https://x.com/investseekers/status/2116925198037360901?a=cABivj0XLJwVLdUOItc&s=20
·11 t sittenNovo Nordisk is expected to launch the oral Wegovy treatment in Poland on Monday, November 2, 2026 – the same day as in France. This is according to the Polish pharmacy platform GdziePoLek, citing the manufacturer. Poland is an attractive market for obesity treatment: Approximately 21.8% of the adult population in Poland lives with obesity according to WHO (2024). The Polish market for GLP-1 preparations and related treatments for diabetes and obesity reached a turnover of 3.39 billion PLN in 2025 compared to 1.79 billion PLN in 2024. This corresponds to a growth of around 89%. Semaglutide preparations accounted for 1.45 billion PLN, corresponding to approximately 43% of the market's total value. Eli Lilly's Mounjaro had a turnover of 1.6 billion PLN in Poland in 2025. The launch of Wegovy as a daily tablet follows the introduction of Wegovy 7.2 mg as a weekly injection treatment in Poland on September 21, 2026.
·19 t sittenhttps://proinvestor.com/forum/topic/560186/novos-defensive-mestertr%C3%A6k-k%C3%B8ber-sig-til-20-%C3%A5rs-ekstra-monopol-p%C3%A5-fedmemarkedet?fbclid=IwZnRzaAVTQsRleHRuA2FlbQIxMQBwZG9mAWZkaWQWURWwDGyk5NDePCD3FanNSgJv_o3i6nNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR-SguU4dNQ93fZpI-fm7G6X0JsaWJuOinFRAQFdYR-zNOU6N99ijvNitd1G5w_aem_QmeM8A9WkiucKg3CdXCXug "A cash injection of a billion and a technology borrowed from the microchip industry. The collaboration between Novo Nordisk and Swedish Nanexa is about much more than just reducing the number of injections – it is a cynical and brilliant defensive maneuver in the global obesity war that can reset the patent clock and pull the rug out from under generic manufacturers. By Helge Larsen, editor and HanneP, science journalist October 31, 2026 The biotech industry and financial world opened their eyes when the Danish pharmaceutical giant Novo on September 24, 2026 entered into a global licensing and collaboration agreement with the smaller Swedish biotech company Nanexa (the news of the agreement did not, however, come as a huge surprise to users on Proinvestor.com, who had long debated the possibility of this happening). The agreement has a staggering potential total value of up to 1.165 billion euros (approx. 8.7 billion kroner). The most striking thing, however, is the cash upfront payment of a whopping 615 million euros (approx. 4.6 billion kroner). That Novo Nordisk is putting such a massive billion-dollar amount on the table up-front for a smaller development company is extremely rare. It testifies to a strategic necessity and a towering confidence in the technology. The probability of commercial success is assessed as significantly higher than average for early biotech deals, because the agreement covers up to five different development programs. If even just one of these projects makes it all the way to the market, the deal is a gigantic commercial success for Nanexa via the subsequent royalties. But what is it exactly that makes Nanexa's patented PharmaShell® technology so special, and what does Novo Nordisk want to get out of the collaboration? The biological problem: The fragility of peptides To understand Novo's billion-dollar bet, one must dive into the mechanics behind modern obesity and diabetes medicine such as Wegovy and Ozempic. These drugs are based on GLP-1 receptor agonists – a type of biological molecules called peptides. Peptider are extremely effective, but they have a major weakness: They are quickly degraded in the body. To turn the medicine into depot medicine that only needs to be taken e.g. once a month or every quarter, one has to wrap the molecules in a protective material that releases them slowly. For decades, the pharmaceutical industry has used polymer-based systems (a kind of biodegradable plastic called PLGA). The traditional methods, however, have three fundamental problems that until now have blocked ultra-long-acting GLP-1 injections: • The acid trap: When the polymers degrade in the body, they form a local acidic environment. This destroys the sensitive peptides before they manage to be released into the bloodstream. • The "burst effect": Traditional depot medicine often releases far too large an amount of medicine in the first hours after the injection (a concentration peak), which for GLP-1 medicine results in severe, unacceptable nausea and vomiting in the patient. • Thick needles: To get enough medicine into the body with traditional excipients, the liquid volume must be large. This requires thick cannulas that must be pressed deep into the muscle (intramuscularly). The solution: Microchip technology in the bloodstream Nanexa solves all these problems at once with PharmaShell®. The technology is originally borrowed from the microchip industry and is called Atomic Layer Deposition (ALD). Instead of mixing the medicine into a large amount of gel or polymer plastic, Nanexa coats each individual microscopic medicine molecule with an inorganic shell that is only a few nanometers thick. This creates a series of unique advantages that distinguish PharmaShell® markedly from traditional depot systems: • Extremely high drug concentration (Drug Load): While traditional depot systems typically only contain 20-30% active medicine and 70-80% fillers, PharmaShell® turns it around. Here, the medicine itself constitutes up to 70-80% of the content. • Ultra-thin needles (High patient comfort): Because the liquid volume becomes extremely small, the medicine can be injected with completely ordinary, ultra-thin cannulas and standard pens (such as those Novo Nordisk uses for Wegovy/Ozempic) just under the skin (subcutaneously). • Chemical neutrality and stability: The inorganic nano-shell completely protects the peptides and dissolves without changing the local chemical environment, which keeps semaglutide stable.“A markedly better side effect profile When patients today experience side effects from Wegovy or Ozempic – primarily in the form of nausea, vomiting, diarrhea and stomach cramps – it is largely due to the concentration peaks in the blood. PharmaShell® is expected to significantly improve this side effect profile on three points: Elimination of "peak side effects": By removing the initial peak load (the burst effect) and instead releasing the medicine in a completely smooth, flat curve, it is expected that a very large part of the acute nausea will disappear. End to the difficult dose-escalation phase: Today, patients must go through a long and often cumbersome dose-escalation period of 4-5 months to get the body used to the medicine. With a stable, controlled release over weeks or months, the dose-escalation phase can potentially be made much shorter and more tolerable. Minimal local irritation: The inorganic nano-shell is extremely biocompatible. When the shell dissolves, it leaves no acid or waste products, which minimizes the risk of redness, itching or hard lumps at the injection site. The new risk: "Point of no return" Although the side effect profile is expected to improve, an ultra-long-acting injection introduces one new clinical challenge: If a patient unexpectedly still gets severe side effects, the medicine cannot be "pulled out" again. Once you have received a 3-month depot injection, the medicine will be in the body for all 3 months. Therefore, it will likely require that patients in the future are first tested on a weekly or short-acting version to prove that they can tolerate the substance before the doctor prescribes the depot version. Golden egg or momentum trap? For Nanexa shareholders, the Novo deal has been a complete game changer, but in financial circles and among equity analysts, the view of the company is characterized by a sharp division between technological euphoria and financial realism. Analysts point out that the deal validates the company's raison d'être. The massive up-front payment completely removes the acute need for ongoing and diluting rights issues, which otherwise plague smaller biotech companies in the development phase. The company has gone from being an extremely risky and loss-making biotech penny stock to being a funded development house with the stamp of approval from the world's largest pharmaceutical company. Several quantitative analysis models have therefore reacted with strong buy signals due to the explosive price increase. More fundamental and long-term equity analysts, however, urge caution. Although the technology is financially secured, the analysts remind us that Nanexa still operates with limited commercial revenue apart from the milestone payments. Consensus among the analysts who cover the stock most closely lies with an average target price that actually reflects some skepticism about how fast the actual royalty revenues will roll in. Because biotech timelines are notoriously long and the company has historically had a hard time reaching regular profitability (breakeven), several institutional houses warn that the stock must still be considered an "extremely speculative" investment. The long-term price development now depends 100% on the clinical trials together with Novo proceeding without technological bumps along the way. Caption: While the financial charts and quantitative models have lit up green after the multibillion-dollar deal, long-term analysts remind us that the road to regular royalty revenues in the biotech sector is a years-long test of patience. Novo Nordisk's choice of Nanexa is a textbook example of strategic biotech synergy. Novo has the biological supermolecules (the peptides) and the global commercial muscle. Nanexa has the physical "packaging" that makes it possible to deliver these molecules to the body over a long period of time without compromising patient comfort. For Novo Nordisk, the billions are an insurance premium, a patent extension and a direct defensive maneuver against Eli Lilly. It is a shortcut to becoming the first in the world to deliver a painless, monthly obesity treatment with minimal nausea. Disclaimer: Helge Larsen holds shares in Novo and Nanexa. The post is not a solicitation to buy and sell shares.”
·21 t sittenHello ..SAME SHIT ! Write something more Wildly funny to see your vocabulary of 100. And the clown head fits you nicely too. ——- And congratulations you are approved as a lackey for Ms A ….She lacks lackeys the little copy/paster She has gotten Novo to Israel and no doubt Novo goes up 10. kr . Strong hands lift Novo 🎩🐇 007 = Same shit.
FX23 you managed to make the week's most worthless comment and that says quite a bit in this forum, that you ( and read you ) do not understand to have more respect for each other's opinions is incomprehensible, but a personal attack belongs nowhere. We can all disagree on the outcome, some see Novo as bad and others see a great potential that does not make each other worse investors, as we all have different strategies This is not a competition about converting the opposite party but about arguing so that the opposite party sees Novo in a different light and perhaps from there gets a different view And let me make it completely clear, I am neither for the one or the other in this forum, other than for a good tone.- ·1 päivä sitten · MuokattuNovo has launched Wegovy as a pill in Israel Novo Nordisk launched the oral Wegovy pill in Israel on October 28, 2026 according to Israeli media. Both N12 and Israel Hayom had previously reported that the Wegovy pill was scheduled to be launched in Israel on October 28, so the launch was already expected. The once-daily semaglutide treatment is initially distributed through private pharmacies and requires a prescription. The price for a month's treatment ranges between 760 and 1,260 Israeli shekels (NIS) (corresponding to approximately 242–401 USD, 217–359 EUR, or 180–299 GBP), depending on the dosage. The launch marks yet another step in Novo Nordisk's international rollout of oral obesity treatments and strengthens the company's commercial position in the rapidly growing GLP-1 market.Too bad Novo doesn't step on the gas a bit more regarding publication. I haven't seen that news anywhere before you can read it here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
88 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,40%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenI have summarized this week's most important Novo news in this post: https://x.com/investseekers/status/2116925198037360901?a=cABivj0XLJwVLdUOItc&s=20
- ·11 t sittenNovo Nordisk is expected to launch the oral Wegovy treatment in Poland on Monday, November 2, 2026 – the same day as in France. This is according to the Polish pharmacy platform GdziePoLek, citing the manufacturer. Poland is an attractive market for obesity treatment: Approximately 21.8% of the adult population in Poland lives with obesity according to WHO (2024). The Polish market for GLP-1 preparations and related treatments for diabetes and obesity reached a turnover of 3.39 billion PLN in 2025 compared to 1.79 billion PLN in 2024. This corresponds to a growth of around 89%. Semaglutide preparations accounted for 1.45 billion PLN, corresponding to approximately 43% of the market's total value. Eli Lilly's Mounjaro had a turnover of 1.6 billion PLN in Poland in 2025. The launch of Wegovy as a daily tablet follows the introduction of Wegovy 7.2 mg as a weekly injection treatment in Poland on September 21, 2026.
- ·19 t sittenhttps://proinvestor.com/forum/topic/560186/novos-defensive-mestertr%C3%A6k-k%C3%B8ber-sig-til-20-%C3%A5rs-ekstra-monopol-p%C3%A5-fedmemarkedet?fbclid=IwZnRzaAVTQsRleHRuA2FlbQIxMQBwZG9mAWZkaWQWURWwDGyk5NDePCD3FanNSgJv_o3i6nNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR-SguU4dNQ93fZpI-fm7G6X0JsaWJuOinFRAQFdYR-zNOU6N99ijvNitd1G5w_aem_QmeM8A9WkiucKg3CdXCXug "A cash injection of a billion and a technology borrowed from the microchip industry. The collaboration between Novo Nordisk and Swedish Nanexa is about much more than just reducing the number of injections – it is a cynical and brilliant defensive maneuver in the global obesity war that can reset the patent clock and pull the rug out from under generic manufacturers. By Helge Larsen, editor and HanneP, science journalist October 31, 2026 The biotech industry and financial world opened their eyes when the Danish pharmaceutical giant Novo on September 24, 2026 entered into a global licensing and collaboration agreement with the smaller Swedish biotech company Nanexa (the news of the agreement did not, however, come as a huge surprise to users on Proinvestor.com, who had long debated the possibility of this happening). The agreement has a staggering potential total value of up to 1.165 billion euros (approx. 8.7 billion kroner). The most striking thing, however, is the cash upfront payment of a whopping 615 million euros (approx. 4.6 billion kroner). That Novo Nordisk is putting such a massive billion-dollar amount on the table up-front for a smaller development company is extremely rare. It testifies to a strategic necessity and a towering confidence in the technology. The probability of commercial success is assessed as significantly higher than average for early biotech deals, because the agreement covers up to five different development programs. If even just one of these projects makes it all the way to the market, the deal is a gigantic commercial success for Nanexa via the subsequent royalties. But what is it exactly that makes Nanexa's patented PharmaShell® technology so special, and what does Novo Nordisk want to get out of the collaboration? The biological problem: The fragility of peptides To understand Novo's billion-dollar bet, one must dive into the mechanics behind modern obesity and diabetes medicine such as Wegovy and Ozempic. These drugs are based on GLP-1 receptor agonists – a type of biological molecules called peptides. Peptider are extremely effective, but they have a major weakness: They are quickly degraded in the body. To turn the medicine into depot medicine that only needs to be taken e.g. once a month or every quarter, one has to wrap the molecules in a protective material that releases them slowly. For decades, the pharmaceutical industry has used polymer-based systems (a kind of biodegradable plastic called PLGA). The traditional methods, however, have three fundamental problems that until now have blocked ultra-long-acting GLP-1 injections: • The acid trap: When the polymers degrade in the body, they form a local acidic environment. This destroys the sensitive peptides before they manage to be released into the bloodstream. • The "burst effect": Traditional depot medicine often releases far too large an amount of medicine in the first hours after the injection (a concentration peak), which for GLP-1 medicine results in severe, unacceptable nausea and vomiting in the patient. • Thick needles: To get enough medicine into the body with traditional excipients, the liquid volume must be large. This requires thick cannulas that must be pressed deep into the muscle (intramuscularly). The solution: Microchip technology in the bloodstream Nanexa solves all these problems at once with PharmaShell®. The technology is originally borrowed from the microchip industry and is called Atomic Layer Deposition (ALD). Instead of mixing the medicine into a large amount of gel or polymer plastic, Nanexa coats each individual microscopic medicine molecule with an inorganic shell that is only a few nanometers thick. This creates a series of unique advantages that distinguish PharmaShell® markedly from traditional depot systems: • Extremely high drug concentration (Drug Load): While traditional depot systems typically only contain 20-30% active medicine and 70-80% fillers, PharmaShell® turns it around. Here, the medicine itself constitutes up to 70-80% of the content. • Ultra-thin needles (High patient comfort): Because the liquid volume becomes extremely small, the medicine can be injected with completely ordinary, ultra-thin cannulas and standard pens (such as those Novo Nordisk uses for Wegovy/Ozempic) just under the skin (subcutaneously). • Chemical neutrality and stability: The inorganic nano-shell completely protects the peptides and dissolves without changing the local chemical environment, which keeps semaglutide stable.“A markedly better side effect profile When patients today experience side effects from Wegovy or Ozempic – primarily in the form of nausea, vomiting, diarrhea and stomach cramps – it is largely due to the concentration peaks in the blood. PharmaShell® is expected to significantly improve this side effect profile on three points: Elimination of "peak side effects": By removing the initial peak load (the burst effect) and instead releasing the medicine in a completely smooth, flat curve, it is expected that a very large part of the acute nausea will disappear. End to the difficult dose-escalation phase: Today, patients must go through a long and often cumbersome dose-escalation period of 4-5 months to get the body used to the medicine. With a stable, controlled release over weeks or months, the dose-escalation phase can potentially be made much shorter and more tolerable. Minimal local irritation: The inorganic nano-shell is extremely biocompatible. When the shell dissolves, it leaves no acid or waste products, which minimizes the risk of redness, itching or hard lumps at the injection site. The new risk: "Point of no return" Although the side effect profile is expected to improve, an ultra-long-acting injection introduces one new clinical challenge: If a patient unexpectedly still gets severe side effects, the medicine cannot be "pulled out" again. Once you have received a 3-month depot injection, the medicine will be in the body for all 3 months. Therefore, it will likely require that patients in the future are first tested on a weekly or short-acting version to prove that they can tolerate the substance before the doctor prescribes the depot version. Golden egg or momentum trap? For Nanexa shareholders, the Novo deal has been a complete game changer, but in financial circles and among equity analysts, the view of the company is characterized by a sharp division between technological euphoria and financial realism. Analysts point out that the deal validates the company's raison d'être. The massive up-front payment completely removes the acute need for ongoing and diluting rights issues, which otherwise plague smaller biotech companies in the development phase. The company has gone from being an extremely risky and loss-making biotech penny stock to being a funded development house with the stamp of approval from the world's largest pharmaceutical company. Several quantitative analysis models have therefore reacted with strong buy signals due to the explosive price increase. More fundamental and long-term equity analysts, however, urge caution. Although the technology is financially secured, the analysts remind us that Nanexa still operates with limited commercial revenue apart from the milestone payments. Consensus among the analysts who cover the stock most closely lies with an average target price that actually reflects some skepticism about how fast the actual royalty revenues will roll in. Because biotech timelines are notoriously long and the company has historically had a hard time reaching regular profitability (breakeven), several institutional houses warn that the stock must still be considered an "extremely speculative" investment. The long-term price development now depends 100% on the clinical trials together with Novo proceeding without technological bumps along the way. Caption: While the financial charts and quantitative models have lit up green after the multibillion-dollar deal, long-term analysts remind us that the road to regular royalty revenues in the biotech sector is a years-long test of patience. Novo Nordisk's choice of Nanexa is a textbook example of strategic biotech synergy. Novo has the biological supermolecules (the peptides) and the global commercial muscle. Nanexa has the physical "packaging" that makes it possible to deliver these molecules to the body over a long period of time without compromising patient comfort. For Novo Nordisk, the billions are an insurance premium, a patent extension and a direct defensive maneuver against Eli Lilly. It is a shortcut to becoming the first in the world to deliver a painless, monthly obesity treatment with minimal nausea. Disclaimer: Helge Larsen holds shares in Novo and Nanexa. The post is not a solicitation to buy and sell shares.”
- ·21 t sittenHello ..SAME SHIT ! Write something more Wildly funny to see your vocabulary of 100. And the clown head fits you nicely too. ——- And congratulations you are approved as a lackey for Ms A ….She lacks lackeys the little copy/paster She has gotten Novo to Israel and no doubt Novo goes up 10. kr . Strong hands lift Novo 🎩🐇 007 = Same shit.FX23 you managed to make the week's most worthless comment and that says quite a bit in this forum, that you ( and read you ) do not understand to have more respect for each other's opinions is incomprehensible, but a personal attack belongs nowhere. We can all disagree on the outcome, some see Novo as bad and others see a great potential that does not make each other worse investors, as we all have different strategies This is not a competition about converting the opposite party but about arguing so that the opposite party sees Novo in a different light and perhaps from there gets a different view And let me make it completely clear, I am neither for the one or the other in this forum, other than for a good tone.
- ·1 päivä sitten · MuokattuNovo has launched Wegovy as a pill in Israel Novo Nordisk launched the oral Wegovy pill in Israel on October 28, 2026 according to Israeli media. Both N12 and Israel Hayom had previously reported that the Wegovy pill was scheduled to be launched in Israel on October 28, so the launch was already expected. The once-daily semaglutide treatment is initially distributed through private pharmacies and requires a prescription. The price for a month's treatment ranges between 760 and 1,260 Israeli shekels (NIS) (corresponding to approximately 242–401 USD, 217–359 EUR, or 180–299 GBP), depending on the dosage. The launch marks yet another step in Novo Nordisk's international rollout of oral obesity treatments and strengthens the company's commercial position in the rapidly growing GLP-1 market.Too bad Novo doesn't step on the gas a bit more regarding publication. I haven't seen that news anywhere before you can read it here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 400 | ||
| 5 237 | ||
| 6 000 | ||
| 6 000 | ||
| 6 000 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
88 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
3,75 DKK/osake
Viimeisin osinko
4,40%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenI have summarized this week's most important Novo news in this post: https://x.com/investseekers/status/2116925198037360901?a=cABivj0XLJwVLdUOItc&s=20
- ·11 t sittenNovo Nordisk is expected to launch the oral Wegovy treatment in Poland on Monday, November 2, 2026 – the same day as in France. This is according to the Polish pharmacy platform GdziePoLek, citing the manufacturer. Poland is an attractive market for obesity treatment: Approximately 21.8% of the adult population in Poland lives with obesity according to WHO (2024). The Polish market for GLP-1 preparations and related treatments for diabetes and obesity reached a turnover of 3.39 billion PLN in 2025 compared to 1.79 billion PLN in 2024. This corresponds to a growth of around 89%. Semaglutide preparations accounted for 1.45 billion PLN, corresponding to approximately 43% of the market's total value. Eli Lilly's Mounjaro had a turnover of 1.6 billion PLN in Poland in 2025. The launch of Wegovy as a daily tablet follows the introduction of Wegovy 7.2 mg as a weekly injection treatment in Poland on September 21, 2026.
- ·19 t sittenhttps://proinvestor.com/forum/topic/560186/novos-defensive-mestertr%C3%A6k-k%C3%B8ber-sig-til-20-%C3%A5rs-ekstra-monopol-p%C3%A5-fedmemarkedet?fbclid=IwZnRzaAVTQsRleHRuA2FlbQIxMQBwZG9mAWZkaWQWURWwDGyk5NDePCD3FanNSgJv_o3i6nNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR-SguU4dNQ93fZpI-fm7G6X0JsaWJuOinFRAQFdYR-zNOU6N99ijvNitd1G5w_aem_QmeM8A9WkiucKg3CdXCXug "A cash injection of a billion and a technology borrowed from the microchip industry. The collaboration between Novo Nordisk and Swedish Nanexa is about much more than just reducing the number of injections – it is a cynical and brilliant defensive maneuver in the global obesity war that can reset the patent clock and pull the rug out from under generic manufacturers. By Helge Larsen, editor and HanneP, science journalist October 31, 2026 The biotech industry and financial world opened their eyes when the Danish pharmaceutical giant Novo on September 24, 2026 entered into a global licensing and collaboration agreement with the smaller Swedish biotech company Nanexa (the news of the agreement did not, however, come as a huge surprise to users on Proinvestor.com, who had long debated the possibility of this happening). The agreement has a staggering potential total value of up to 1.165 billion euros (approx. 8.7 billion kroner). The most striking thing, however, is the cash upfront payment of a whopping 615 million euros (approx. 4.6 billion kroner). That Novo Nordisk is putting such a massive billion-dollar amount on the table up-front for a smaller development company is extremely rare. It testifies to a strategic necessity and a towering confidence in the technology. The probability of commercial success is assessed as significantly higher than average for early biotech deals, because the agreement covers up to five different development programs. If even just one of these projects makes it all the way to the market, the deal is a gigantic commercial success for Nanexa via the subsequent royalties. But what is it exactly that makes Nanexa's patented PharmaShell® technology so special, and what does Novo Nordisk want to get out of the collaboration? The biological problem: The fragility of peptides To understand Novo's billion-dollar bet, one must dive into the mechanics behind modern obesity and diabetes medicine such as Wegovy and Ozempic. These drugs are based on GLP-1 receptor agonists – a type of biological molecules called peptides. Peptider are extremely effective, but they have a major weakness: They are quickly degraded in the body. To turn the medicine into depot medicine that only needs to be taken e.g. once a month or every quarter, one has to wrap the molecules in a protective material that releases them slowly. For decades, the pharmaceutical industry has used polymer-based systems (a kind of biodegradable plastic called PLGA). The traditional methods, however, have three fundamental problems that until now have blocked ultra-long-acting GLP-1 injections: • The acid trap: When the polymers degrade in the body, they form a local acidic environment. This destroys the sensitive peptides before they manage to be released into the bloodstream. • The "burst effect": Traditional depot medicine often releases far too large an amount of medicine in the first hours after the injection (a concentration peak), which for GLP-1 medicine results in severe, unacceptable nausea and vomiting in the patient. • Thick needles: To get enough medicine into the body with traditional excipients, the liquid volume must be large. This requires thick cannulas that must be pressed deep into the muscle (intramuscularly). The solution: Microchip technology in the bloodstream Nanexa solves all these problems at once with PharmaShell®. The technology is originally borrowed from the microchip industry and is called Atomic Layer Deposition (ALD). Instead of mixing the medicine into a large amount of gel or polymer plastic, Nanexa coats each individual microscopic medicine molecule with an inorganic shell that is only a few nanometers thick. This creates a series of unique advantages that distinguish PharmaShell® markedly from traditional depot systems: • Extremely high drug concentration (Drug Load): While traditional depot systems typically only contain 20-30% active medicine and 70-80% fillers, PharmaShell® turns it around. Here, the medicine itself constitutes up to 70-80% of the content. • Ultra-thin needles (High patient comfort): Because the liquid volume becomes extremely small, the medicine can be injected with completely ordinary, ultra-thin cannulas and standard pens (such as those Novo Nordisk uses for Wegovy/Ozempic) just under the skin (subcutaneously). • Chemical neutrality and stability: The inorganic nano-shell completely protects the peptides and dissolves without changing the local chemical environment, which keeps semaglutide stable.“A markedly better side effect profile When patients today experience side effects from Wegovy or Ozempic – primarily in the form of nausea, vomiting, diarrhea and stomach cramps – it is largely due to the concentration peaks in the blood. PharmaShell® is expected to significantly improve this side effect profile on three points: Elimination of "peak side effects": By removing the initial peak load (the burst effect) and instead releasing the medicine in a completely smooth, flat curve, it is expected that a very large part of the acute nausea will disappear. End to the difficult dose-escalation phase: Today, patients must go through a long and often cumbersome dose-escalation period of 4-5 months to get the body used to the medicine. With a stable, controlled release over weeks or months, the dose-escalation phase can potentially be made much shorter and more tolerable. Minimal local irritation: The inorganic nano-shell is extremely biocompatible. When the shell dissolves, it leaves no acid or waste products, which minimizes the risk of redness, itching or hard lumps at the injection site. The new risk: "Point of no return" Although the side effect profile is expected to improve, an ultra-long-acting injection introduces one new clinical challenge: If a patient unexpectedly still gets severe side effects, the medicine cannot be "pulled out" again. Once you have received a 3-month depot injection, the medicine will be in the body for all 3 months. Therefore, it will likely require that patients in the future are first tested on a weekly or short-acting version to prove that they can tolerate the substance before the doctor prescribes the depot version. Golden egg or momentum trap? For Nanexa shareholders, the Novo deal has been a complete game changer, but in financial circles and among equity analysts, the view of the company is characterized by a sharp division between technological euphoria and financial realism. Analysts point out that the deal validates the company's raison d'être. The massive up-front payment completely removes the acute need for ongoing and diluting rights issues, which otherwise plague smaller biotech companies in the development phase. The company has gone from being an extremely risky and loss-making biotech penny stock to being a funded development house with the stamp of approval from the world's largest pharmaceutical company. Several quantitative analysis models have therefore reacted with strong buy signals due to the explosive price increase. More fundamental and long-term equity analysts, however, urge caution. Although the technology is financially secured, the analysts remind us that Nanexa still operates with limited commercial revenue apart from the milestone payments. Consensus among the analysts who cover the stock most closely lies with an average target price that actually reflects some skepticism about how fast the actual royalty revenues will roll in. Because biotech timelines are notoriously long and the company has historically had a hard time reaching regular profitability (breakeven), several institutional houses warn that the stock must still be considered an "extremely speculative" investment. The long-term price development now depends 100% on the clinical trials together with Novo proceeding without technological bumps along the way. Caption: While the financial charts and quantitative models have lit up green after the multibillion-dollar deal, long-term analysts remind us that the road to regular royalty revenues in the biotech sector is a years-long test of patience. Novo Nordisk's choice of Nanexa is a textbook example of strategic biotech synergy. Novo has the biological supermolecules (the peptides) and the global commercial muscle. Nanexa has the physical "packaging" that makes it possible to deliver these molecules to the body over a long period of time without compromising patient comfort. For Novo Nordisk, the billions are an insurance premium, a patent extension and a direct defensive maneuver against Eli Lilly. It is a shortcut to becoming the first in the world to deliver a painless, monthly obesity treatment with minimal nausea. Disclaimer: Helge Larsen holds shares in Novo and Nanexa. The post is not a solicitation to buy and sell shares.”
- ·21 t sittenHello ..SAME SHIT ! Write something more Wildly funny to see your vocabulary of 100. And the clown head fits you nicely too. ——- And congratulations you are approved as a lackey for Ms A ….She lacks lackeys the little copy/paster She has gotten Novo to Israel and no doubt Novo goes up 10. kr . Strong hands lift Novo 🎩🐇 007 = Same shit.FX23 you managed to make the week's most worthless comment and that says quite a bit in this forum, that you ( and read you ) do not understand to have more respect for each other's opinions is incomprehensible, but a personal attack belongs nowhere. We can all disagree on the outcome, some see Novo as bad and others see a great potential that does not make each other worse investors, as we all have different strategies This is not a competition about converting the opposite party but about arguing so that the opposite party sees Novo in a different light and perhaps from there gets a different view And let me make it completely clear, I am neither for the one or the other in this forum, other than for a good tone.
- ·1 päivä sitten · MuokattuNovo has launched Wegovy as a pill in Israel Novo Nordisk launched the oral Wegovy pill in Israel on October 28, 2026 according to Israeli media. Both N12 and Israel Hayom had previously reported that the Wegovy pill was scheduled to be launched in Israel on October 28, so the launch was already expected. The once-daily semaglutide treatment is initially distributed through private pharmacies and requires a prescription. The price for a month's treatment ranges between 760 and 1,260 Israeli shekels (NIS) (corresponding to approximately 242–401 USD, 217–359 EUR, or 180–299 GBP), depending on the dosage. The launch marks yet another step in Novo Nordisk's international rollout of oral obesity treatments and strengthens the company's commercial position in the rapidly growing GLP-1 market.Too bad Novo doesn't step on the gas a bit more regarding publication. I haven't seen that news anywhere before you can read it here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 400 | ||
| 5 237 | ||
| 6 000 | ||
| 6 000 | ||
| 6 000 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt